PriceTargets.com logo

BeiGene - BGNE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $247.07
  • Forecasted Upside: 27.19%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$194.26 As of 11/20/2024 01:00 AM ET
▲ +6.49 (3.46%)

This chart shows the closing price for BGNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BeiGene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BGNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BGNE

Analyst Price Target is $247.07
▲ +27.19% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for BeiGene in the last 3 months. The average price target is $247.07, with a high forecast of $345.00 and a low forecast of $152.50. The average price target represents a 27.19% upside from the last price of $194.26.

This chart shows the closing price for BGNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in BeiGene. This rating has held steady since April 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024TD CowenBoost TargetBuy ➝ Buy$254.00 ➝ $260.00
10/22/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$200.00 ➝ $235.00
9/18/2024JMP SecuritiesInitiated CoverageMarket Outperform$288.00
8/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$194.00 ➝ $200.00
8/8/2024CitigroupBoost TargetBuy ➝ Buy$269.00 ➝ $288.00
7/9/2024Bank of AmericaLower TargetNeutral ➝ Neutral$180.00 ➝ $152.50
5/9/2024TD CowenBoost TargetBuy ➝ Buy$236.00 ➝ $254.00
4/24/2024TD CowenBoost TargetBuy ➝ Buy$235.00 ➝ $236.00
4/8/2024Bank of AmericaLower TargetNeutral ➝ Neutral$179.30 ➝ $164.30
3/27/2024Sanford C. BernsteinLower TargetMarket Perform ➝ Market Perform$196.00 ➝ $161.00
3/19/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$184.00 ➝ $186.00
2/27/2024GuggenheimLower TargetBuy ➝ Buy$350.00 ➝ $345.00
2/6/2024JPMorgan Chase & Co.Reiterated RatingOverweight$185.00
10/26/2023CitigroupLower TargetBuy ➝ Buy$290.00 ➝ $285.00
9/21/2023CitigroupBoost TargetBuy ➝ Buy$285.00 ➝ $290.00
9/20/2023Bank of AmericaLower TargetNeutral ➝ Neutral$224.13 ➝ $212.00
9/12/2023Royal Bank of CanadaInitiated CoverageOutperform$259.00
9/11/2023MacquarieInitiated CoverageOutperform$259.00
8/29/2023Morgan StanleyLower TargetOverweight ➝ Overweight$321.00 ➝ $319.00
8/17/2023Jefferies Financial GroupInitiated CoverageBuy$287.00
8/7/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$297.00 ➝ $300.00
7/17/2023CitigroupInitiated CoverageBuy$275.00
6/30/202351jobReiterated RatingDowngrade
6/30/202322nd Century GroupReiterated RatingDowngrade
6/30/20233MReiterated RatingDowngrade
6/30/2023Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$335.00 ➝ $196.00
4/12/2023Bank of AmericaBoost TargetNeutral$230.10 ➝ $263.30
2/28/2023GuggenheimReiterated RatingBuy$350.00
2/28/2023Morgan StanleyLower TargetOverweight$325.00 ➝ $321.00
2/28/2023CowenBoost TargetOutperform$213.00 ➝ $262.00
1/24/2023Morgan StanleyBoost TargetOverweight$295.00 ➝ $325.00
1/20/2023Leerink PartnersBoost TargetOutperform$236.00 ➝ $300.00
1/20/2023GuggenheimBoost TargetBuy$290.00 ➝ $350.00
1/11/2023Daiwa Capital MarketsInitiated CoverageBuy$308.00
12/12/2022Leerink PartnersBoost TargetOutperform$210.00 ➝ $236.00
11/15/2022GuggenheimBoost Target$210.00
11/10/2022CowenBoost Target$200.00 ➝ $213.00
11/10/2022Leerink PartnersBoost TargetOutperform$200.00 ➝ $210.00
11/10/2022CowenBoost Target$200.00 ➝ $213.00
10/13/2022Morgan StanleyBoost TargetOverweight$290.00 ➝ $295.00
10/13/2022GuggenheimUpgradeNeutral ➝ Buy$205.00
10/12/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$177.00 ➝ $200.00
8/9/2022JPMorgan Chase & Co.Reiterated RatingOverweight$296.00
7/15/2022Morgan StanleyLower TargetOverweight$300.00 ➝ $293.00
4/12/2022Morgan StanleyBoost TargetOverweight$330.00 ➝ $338.00
3/17/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$300.00 ➝ $177.00
2/28/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00
2/28/2022Leerink PartnersLower TargetOutperform$334.00 ➝ $300.00
2/7/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy
1/18/2022Morgan StanleyLower TargetOverweight$407.00 ➝ $360.00
1/13/2022JPMorgan Chase & Co.Initiated CoverageOverweight
10/14/2021Leerink PartnersLower TargetOutperform$417.00 ➝ $414.00
10/12/2021Sanford C. BernsteinInitiated CoverageOutperform$431.00
10/6/2021CLSAUpgradeUnderperform ➝ Buy
8/16/2021Morgan StanleyLower TargetOverweight$409.00 ➝ $407.00
6/14/2021Leerink PartnersBoost TargetPositive ➝ Outperform$388.00 ➝ $417.00
6/3/2021Morgan StanleyBoost TargetOverweight$357.00 ➝ $409.00
5/10/2021Morgan StanleyLower TargetOverweight$375.00 ➝ $357.00
3/16/2021HSBCBoost TargetBuy$296.00 ➝ $385.00
3/1/2021CLSADowngradeOutperform ➝ Underperform$330.00 ➝ $321.00
2/18/2021CowenBoost TargetOutperform$348.00 ➝ $429.00
1/19/2021Morgan StanleyBoost TargetOverweight$310.00 ➝ $375.00
1/12/2021Piper SandlerBoost Target$185.00 ➝ $190.00
12/8/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$278.00
11/19/2020Leerink PartnersBoost TargetOutperform$240.00 ➝ $327.00
11/11/2020Morgan StanleyBoost TargetOverweight$270.00 ➝ $310.00
11/9/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
11/6/2020Maxim GroupDowngradeBuy ➝ Hold
11/6/2020Leerink PartnersBoost TargetOutperform$210.00 ➝ $240.00
11/6/2020Piper SandlerDowngradeNeutral ➝ Underweight$175.00 ➝ $185.00
10/13/2020Morgan StanleyBoost TargetOverweight$241.00 ➝ $270.00
8/10/2020Morgan StanleyBoost TargetOverweight$235.00 ➝ $241.00
8/7/2020LADENBURG THALM/SH SHBoost TargetBuy$232.00 ➝ $268.00
8/6/2020Piper SandlerBoost TargetNeutral$165.00 ➝ $175.00
7/15/2020Morgan StanleyBoost TargetOverweight$190.00 ➝ $235.00
7/10/2020Maxim GroupReiterated RatingPositive ➝ Buy$190.00 ➝ $250.00
6/3/2020Leerink PartnersBoost TargetOutperform$207.00 ➝ $210.00
5/28/2020Morgan StanleyBoost TargetOverweight$184.00 ➝ $190.00
4/15/2020Morgan StanleyLower TargetOverweight$210.00 ➝ $184.00
3/13/2020MacquarieUpgradeUnderperform ➝ Neutral
3/3/2020Maxim GroupLower TargetPositive ➝ Buy$210.00 ➝ $190.00
3/3/2020CowenReiterated RatingBuy$200.00
2/18/2020The Goldman Sachs GroupInitiated CoverageBuy$197.30
1/27/2020CowenReiterated RatingOutperform
1/17/2020Morgan StanleyInitiated CoverageOverweight$210.00
12/16/2019CowenReiterated RatingBuy$216.00
12/16/2019Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$165.00
12/16/2019GuggenheimDowngradeBuy ➝ Neutral
12/10/2019Maxim GroupReiterated RatingBuy$210.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 14 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 14 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 12 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 15 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 17 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
9/21/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 20 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 20 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

BeiGene logo
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Read More

Today's Range

Now: $194.26
Low: $192.00
High: $198.48

50 Day Range

MA: $212.60
Low: $187.69
High: $246.04

52 Week Range

Now: $194.26
Low: $126.97
High: $248.16

Volume

261,727 shs

Average Volume

265,949 shs

Market Capitalization

$18.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of BeiGene?

The following Wall Street sell-side analysts have issued reports on BeiGene in the last year: Bank of America Co., Citigroup Inc., Guggenheim, JMP Securities, JPMorgan Chase & Co., Sanford C. Bernstein, StockNews.com, and TD Cowen.
View the latest analyst ratings for BGNE.

What is the current price target for BeiGene?

0 Wall Street analysts have set twelve-month price targets for BeiGene in the last year. Their average twelve-month price target is $247.07, suggesting a possible upside of 27.2%. Guggenheim has the highest price target set, predicting BGNE will reach $345.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $152.50 for BeiGene in the next year.
View the latest price targets for BGNE.

What is the current consensus analyst rating for BeiGene?

BeiGene currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BGNE.

What other companies compete with BeiGene?

Other companies that are similar to BeiGene include BioMarin Pharmaceutical, Alnylam Pharmaceuticals, GSK, Takeda Pharmaceutical and BioNTech. Learn More about companies similar to BeiGene.

How do I contact BeiGene's investor relations team?

BeiGene's physical mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company's listed phone number is (345) 949-4123 and its investor relations email address is [email protected]. The official website for BeiGene is www.beigene.com. Learn More about contacing BeiGene investor relations.